📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
0 analysed today
FollowTelegram
0
Today
152,139
All-time analysed
43,645
Positive
6,747
Negative
92,898
Neutral
8,781
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
84 announcements match the current filters (relevance ≥ 5).
Lupin Receives European Commission Approval for Biosimilar Ranibizumab (Ranluspec™)
Lupin has received marketing authorization from the European Commission for its biosimilar Ranibizumab, branded as Ranluspec™, available in vials and pre-filled syringes. The approval covers critical ophthalmic indications including wet age-related macular degeneration and diabetic macular edema. Lupin has partnered with Sandoz for commercialization across the European Union (excluding Germany) and with both Sandoz and Biogaran in France. This milestone validates Lupin's biotechnology capabilities and strengthens its portfolio in the high-growth biosimilars market.
Key Highlights
European Commission approval granted for Ranluspec™ (biosimilar Ranibizumab) for multiple ophthalmic indications.
Approval includes both vial and pre-filled syringe formats, enhancing delivery options for healthcare providers.
Strategic commercialization partnership formed with Sandoz for the EU market, excluding Germany.
Specific dual-partner commercialization strategy implemented for the French market with Sandoz and Biogaran.
The product targets high-value therapeutic areas such as neovascular (wet) age-related macular degeneration and diabetic macular edema.
👀 What to Watch
Investors should view this as a significant positive development that expands Lupin's high-margin biologics portfolio in regulated markets. Monitor the commercial rollout and subsequent market share gains in Europe to assess long-term revenue impact.
Lupin Q3 FY26: Record Revenue of ₹7,168 Cr and EBITDA Margin Surges to 31.1%
Lupin delivered a robust Q3 FY26 performance with total revenue growing 24% YoY to INR 7,168 crores, driven by record US sales of USD 350 million. EBITDA margins expanded significantly to 31.1%, up 681 bps YoY, leading management to raise full-year margin guidance to 27%-28%. The US business benefited from new launches like Tolvaptan and Risperdal Consta, while the India prescription business grew 10.9% YoY. The company achieved a strong net cash position of INR 2,879 crores and received its first US biosimilar approval for Pegfilgrastim.
Key Highlights
Revenue from operations grew 24% YoY to INR 7,168 crores, with US sales hitting a record USD 350 million.
EBITDA margins reached 31.1%, an improvement of 681 bps YoY, driven by better product mix and cost efficiencies.
India core prescription business grew 10.9% YoY, with Chronic segments now accounting for 67% of the portfolio.
Emerging markets saw 42% YoY growth, led by a 99% local currency growth in Brazil following the Dapagliflozin launch.
Management raised full-year EBITDA margin guidance to 27%-28% from the previous 25%-26% range.
👀 What to Watch
Investors should view the structural margin expansion and the entry into the US biosimilars market as significant long-term value drivers. The upward revision in guidance and strong cash generation support a positive outlook on the stock.
Lupin Partners with Spektus to Launch Novel Antidepressant DeslaFlex in Canada
Lupin Limited has signed a strategic license and supply agreement with Spektus Pharma to commercialize DeslaFlex™, a novel antidepressant, in the Canadian market. DeslaFlex™ utilizes the proprietary Flexitab™ oral drug-delivery platform to treat Major Depressive Disorder with enhanced dosing flexibility. This partnership leverages Lupin's established commercial infrastructure in Canada to expand its Central Nervous System (CNS) portfolio. The collaboration is part of Lupin's broader strategy to introduce value-added, physician-endorsed specialty therapies in developed markets.
Key Highlights
Exclusive license and supply agreement for the commercialization of DeslaFlex™ in Canada.
Targeted at Major Depressive Disorder using the proprietary Flexitab™ drug-delivery platform.
Strengthens Lupin's CNS portfolio and global specialty business footprint.
Lupin maintains a global presence with 15 manufacturing sites and 7 research centers.
The agreement marks Spektus Pharma's transition from development to commercial execution.
👀 What to Watch
Investors should monitor the commercial rollout and market share gains of DeslaFlex™ in Canada as it represents a high-margin specialty product addition. This move reinforces Lupin's growth potential in the CNS segment within developed markets.
Anand Kripalu Joins Lupin Board as Independent Director
Lupin Limited has appointed Anand Kripalu as an Independent Director to its Board, effective February 13, 2026. Kripalu brings over 30 years of leadership experience from the FMCG sector, having served as MD and Global CEO of EPL Limited and CEO of Diageo India. His extensive background includes 20 years at Unilever and leadership roles at Mondelez International. This appointment is expected to strengthen Lupin's strategic oversight and global market positioning.
Key Highlights
Anand Kripalu appointed as Independent Director with over 30 years of FMCG leadership experience.
Previously served as Managing Director and Global CEO of EPL Limited until December 31, 2025.
Held senior leadership roles at Diageo India (MD & CEO) and Mondelez International (President - India & SE Asia).
Currently serves on the boards of Swiggy Limited and United Breweries Limited.
Educational background includes degrees from IIT Madras and IIM Calcutta, plus an AMP from Wharton.
👀 What to Watch
Investors should view this as a positive corporate governance move that adds significant consumer-market expertise to the board. No immediate action is required, but the appointment may help refine Lupin's domestic and global branding strategies.
Lupin Shareholders Approve Appointment of Anand Kripalu as Independent Director
Lupin Limited has announced that its shareholders have approved the appointment of Mr. Anand Kripalu as an Independent Director through a special resolution. The voting, conducted via postal ballot, saw a high participation rate with 90.17% of total shares represented. The resolution passed with a significant majority, as 96.54% of the total votes cast were in favor of the appointment. This move strengthens the company's board governance with the addition of an experienced professional.
Key Highlights
Special resolution for the appointment of Anand Kripalu passed with 96.54% votes in favor.
Total voter turnout was robust at 90.17%, representing 411,905,910 shares.
Promoter and Promoter Group voted 100% in favor of the resolution with 214.2 million votes.
Public Institutional shareholders supported the move with 92.76% of their votes cast in favor.
The appointment was finalized on February 13, 2026, following the conclusion of the remote e-voting period.
👀 What to Watch
Investors should view this as a positive step in strengthening corporate governance. No immediate portfolio action is required, but the addition of experienced independent directors is generally favorable for long-term oversight.
Lupin Q3 FY26: Net Profit jumps 38% to ₹1,176 Cr; EBITDA margins expand to 31.1%
Lupin reported a robust performance for Q3 FY26, with consolidated revenue growing 26% YoY to ₹7,101 crore, primarily driven by a 46% surge in the US market. EBITDA margins saw a significant expansion to 31.1% from 24.3% in the previous year, reflecting a superior product mix and operational efficiencies. The US business achieved a record quarterly high of $350 million, supported by key launches like gRisperdal Consta. While India growth was moderate at 6%, the company maintained its leadership in chronic segments and improved its net cash position.
Key Highlights
Consolidated Sales grew 26% YoY to ₹71,005 mn, while EBITDA surged 62% YoY to ₹22,095 mn.
US sales reached a record $350 mn, growing 46% YoY, driven by complex generic launches and base business momentum.
EBITDA margins expanded significantly to 31.1% compared to 24.3% in Q3 FY25.
The company is now in a net cash position with a Net Debt to Equity ratio of -0.14.
Received US FDA approval for Armlupeg (biosimilar) and successful inspection outcomes (NAI/VAI) for Nagpur and Aurangabad sites.
👀 What to Watch
Investors should view this as a strong performance, particularly the massive margin expansion and record US sales. The stock remains a key pick in the pharma sector as it successfully pivots toward complex generics and biosimilars.
Lupin Q3 FY26 Results: PAT Up 37% YoY to ₹1,181 Cr; US Sales Surge 54%
Lupin reported a robust performance for Q3 FY26, with consolidated sales growing 26.4% YoY to ₹7,101 crore, driven by record US sales of $350 million. EBITDA margins saw a significant expansion of 840 bps YoY to 33.5%, although they moderated slightly from the previous quarter. Despite a one-time exceptional charge of ₹427 crore, Profit After Tax (PAT) grew 37.4% YoY to ₹1,181 crore. The company remains net debt-free with a strong cash position of ₹2,879 crore.
Key Highlights
Consolidated Sales grew 26.4% YoY to ₹71,005 Mn, led by a 54% surge in US revenue.
EBITDA increased 68.6% YoY to ₹23,766 Mn with margins expanding to 33.5% from 25.1% YoY.
PAT rose 37.4% YoY to ₹11,805 Mn, even after accounting for a ₹4,266 Mn exceptional item.
India formulation sales grew 10.9% YoY, while Global API sales declined 24.1% YoY.
Net Cash position stands at ₹28,793 Mn with a Net Debt to Equity ratio of -0.14.
👀 What to Watch
Investors should focus on the strong US growth and significant margin expansion as key positives. While API sales were weak, the company's robust cash position and leadership in US generics support a positive long-term outlook.
Lupin Q3 FY26 Results: Consolidated Revenue Up 24.3% YoY; Impacted by ₹6.34B Exceptional Charges
Lupin reported a strong operational performance for Q3 FY26 with consolidated revenue growing 24.3% YoY to ₹71,675.2 million. However, the bottom line was significantly impacted by exceptional items totaling ₹6,338.4 million, including a ₹4,493.9 million ($50M) provision for US antitrust litigation and a ₹1,348.1 million ($15M) settlement for Mirabegron ER Tablets. Excluding these one-time costs, standalone profit before tax grew 16% YoY to ₹15,017.8 million, reflecting healthy core business momentum despite regulatory and legal headwinds.
Key Highlights
Consolidated Revenue from operations increased 24.3% YoY to ₹71,675.2 million.
Standalone Profit before exceptional items and tax grew 16% YoY to ₹15,017.8 million.
Recognized a ₹4,493.9 million ($50 million) provision for settling class-action antitrust litigations in the US.
Agreed to a one-time settlement payment of ₹1,348.1 million ($15 million) for Mirabegron ER Tablets dispute.
Accounted for ₹496.4 million in incremental costs due to the implementation of New Labour Codes effective November 2025.
👀 What to Watch
Investors should focus on the robust 24% revenue growth and operational margins while treating the legal provisions as necessary one-time costs to clear litigation overhangs. The stock may see short-term volatility due to the net profit dip, but the underlying business strength remains intact.
Lupin Settles Mirabegron Patent Dispute with Astellas for USD 90 Million
Lupin Limited and its US subsidiary have entered into a settlement and license agreement with Astellas Pharma to resolve patent litigation regarding the drug Mirabegron. Under the agreement, Lupin will pay Astellas a total of USD 90 million, which includes a USD 75 million prepaid option payment. Additionally, Lupin will pay a per-unit license fee for products sold through September 2027. This settlement is significant as it removes legal uncertainty and allows Lupin to continue marketing the product.
Key Highlights
Settlement resolves long-standing patent infringement dispute with Astellas Pharma regarding 'Mirabegron'.
Lupin to pay a total of USD 90 million, including a USD 75 million Prepaid Option Payment.
Agreement includes a Prepaid Per Unit License Fee for each unit sold through September 2027.
The settlement ensures Lupin can continue to sell its Mirabegron product without further litigation risk.
👀 What to Watch
Investors should monitor the impact of the USD 90 million cash outflow on the upcoming quarterly earnings and margins. While the payout is substantial, the resolution of legal risk for a key product provides long-term clarity for the US generic portfolio.
Lupin Launches Topiramate Extended-Release Capsules in US; $164M Market Opportunity
Lupin Limited has launched Topiramate Extended-Release Capsules in the United States following U.S. FDA approval of its Abbreviated New Drug Application (ANDA). The product is a generic version of Trokendi XR® and is available in four strengths ranging from 25 mg to 200 mg. The addressable market for this product in the U.S. is estimated at USD 164 million annually according to IQVIA data. This launch strengthens Lupin's portfolio in the Central Nervous System (CNS) therapeutic segment, a key growth area for the company.
Key Highlights
Launched Topiramate Extended-Release Capsules in 25 mg, 50 mg, 100 mg, and 200 mg strengths.
Product is bioequivalent to the reference drug Trokendi XR® by Supernus Pharmaceuticals.
Estimated annual sales for the product in the U.S. market are USD 164 million as of December 2025.
Indicated for the treatment of seizures in patients 6 years and older and migraine prevention in patients 12 years and older.
👀 What to Watch
Investors should monitor Lupin's ability to capture market share in the CNS segment, as this launch provides a steady revenue stream in the U.S. generics market. The $164 million market size offers a meaningful incremental growth opportunity for the company's North American operations.
Lupin Launches Generic Sprycel (Dasatinib) in US Targeting $930 Million Market
Lupin Limited has launched Dasatinib Tablets in the United States, a generic version of Bristol-Myers Squibb's Sprycel, following US FDA approval. Developed in partnership with Pharmascience Inc., the product is available in six strengths ranging from 20 mg to 140 mg. This launch addresses a significant market opportunity, as the reference drug Sprycel had estimated annual US sales of USD 930 million as of October 2025. The medication is used for treating Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia in both adults and children.
Key Highlights
Launched Dasatinib Tablets in 20mg, 50mg, 70mg, 80mg, 100mg, and 140mg strengths in the US
Targets a market with estimated annual sales of USD 930 million (IQVIA MAT Oct 2025)
Product developed in collaboration with Canadian firm Pharmascience Inc.
Indicated for multiple leukemia treatments including Ph+ CML and Ph+ ALL in adults and pediatric patients
👀 What to Watch
This high-value generic launch is expected to bolster Lupin's US revenue and oncology portfolio. Investors should track the company's ability to capture market share from the innovator and other generic entrants.
Lupin Partners with TB Alliance to Advance Telacebec for Tuberculosis and Mycobacterial Diseases
Lupin has entered into a strategic collaboration with TB Alliance to advance the clinical development and commercialization of Telacebec (formerly Q203). The drug targets major mycobacterial diseases including tuberculosis, leprosy, and Buruli ulcer. While TB Alliance leads the development process, Lupin will leverage its global manufacturing expertise and distribution network across 100+ markets to ensure supply. This partnership strengthens Lupin's position in the anti-infective therapy area and addresses significant unmet medical needs globally.
Key Highlights
Strategic collaboration for Telacebec (Q203) targeting TB, leprosy, and Buruli ulcer
Lupin to provide global manufacturing, regulatory affairs, and supply chain expertise
TB Alliance to continue leading the clinical development process of the investigational drug
Lupin operates 15 manufacturing sites and 7 research centers to support global access
Collaboration aims to provide equitable access to advanced treatments in over 100 markets
👀 What to Watch
Investors should monitor the clinical trial progress of Telacebec as it represents a significant addition to Lupin's anti-infective pipeline. This partnership enhances Lupin's long-term growth prospects in specialized therapy areas and its global ESG standing.
Lupin Achieves Highest Double 'A' ESG Rating from CDP for Climate and Water
Lupin Limited has been awarded the highest 'A' leadership rating by the Climate Disclosure Project (CDP) for both Climate Change and Water Security in 2026. This marks a steady improvement from its 2024 'A-' ratings and 2023 ratings of 'B' for climate and 'C' for water. Furthermore, the company reported an S&P Global ESG score of 91 for 2025, placing it in an elite global bracket of companies surpassing the 90-point threshold. These achievements reflect Lupin's enhanced focus on sustainability, which is increasingly vital for attracting global institutional capital.
Key Highlights
Achieved double 'A' leadership rating from CDP for Climate Change and Water Security in 2026.
Significant multi-year improvement from 2023 ratings of 'B' (Climate) and 'C' (Water).
Secured a best-in-class S&P Global ESG score of 91 in 2025.
Recognition positions Lupin as a global leader in environmental transparency and risk management.
👀 What to Watch
Investors should view this as a positive fundamental development that enhances Lupin's attractiveness to ESG-mandated institutional funds. While it doesn't impact short-term earnings, it strengthens the company's long-term risk profile and global reputation.
Lupin Signs Licensing Deal with Galenicum for Semaglutide in 23 Global Markets
Lupin Limited has entered into a strategic licensing and supply agreement with Galenicum Health for injectable Semaglutide, a high-demand GLP-1 receptor agonist. The partnership covers 23 countries across Canada, Europe, Southeast Asia, and Latin America, positioning Lupin to capture growth in the global diabetes and obesity markets. While Galenicum will manage manufacturing and development, Lupin will leverage its commercial infrastructure for regulatory approvals and distribution. This move significantly strengthens Lupin's specialty portfolio and expands its international footprint in high-growth therapeutic areas.
Key Highlights
Agreement covers the commercialization of injectable Semaglutide in 23 countries globally.
Target markets include major regions such as Canada, Europe, Southeast Asia, and Latin America.
Lupin will handle all regulatory submissions, approvals, and distribution while Galenicum manages manufacturing.
Strategic entry into the GLP-1 market, which is currently one of the fastest-growing segments in pharma for diabetes and obesity.
Lupin's subsidiary, Lupin Atlantis Holdings SA (LAHSA), will execute the agreement.
👀 What to Watch
Investors should view this as a strong strategic move into the lucrative GLP-1 market. Monitor the timeline for regulatory approvals and product launches in the specified 23 countries as these will be the primary drivers for future revenue growth from this deal.
Lupin Appoints FMCG Veteran Anand Kripalu as Independent Director for 5-Year Term
Lupin Limited has announced the appointment of Mr. Anand Kripalu as an Additional Director (Non-Executive, Independent) effective February 1, 2026. Mr. Kripalu brings over 30 years of extensive industry experience, having previously served as MD & CEO of Diageo India and held senior leadership roles at Mondelez and Unilever. His appointment is for a five-year term ending January 31, 2031, subject to shareholder approval. This move is expected to enhance the board's strategic depth given his track record in global consumer-facing industries.
Key Highlights
Appointment of Mr. Anand Kripalu as Independent Director for a 5-year term starting February 1, 2026
Over 30 years of leadership experience in FMCG, including roles at Diageo, Mondelez, and Unilever
Educational background includes B.Tech from IIT Madras, MBA from IIM Calcutta, and AMP from Wharton
Currently serves as Executive Director of EPL Limited and holds board positions at Swiggy and United Breweries
The appointment was unanimously approved by the Board based on the Nomination and Remuneration Committee's recommendation
👀 What to Watch
Investors should view this as a positive step toward strengthening corporate governance and strategic oversight. No immediate portfolio action is required based on this board-level appointment.
Lupin Extends Timeline for VISUfarma B.V. Acquisition to February 2026
Lupin Limited's wholly owned subsidiary, Nanomi B.V., has announced a delay in the acquisition of 100% share capital of VISUfarma B.V., Netherlands. The transaction, which was originally expected to be consummated by the end of calendar year 2025, is now slated for completion by February 28, 2026. The acquisition process is currently in progress and remains subject to specific closing conditions. This update follows the initial definitive agreement signed on September 29, 2025.
Key Highlights
Acquisition of 100% share capital of Amsterdam-based VISUfarma B.V. by Nanomi B.V.
Completion deadline extended from December 31, 2025, to February 28, 2026.
The transaction is currently in progress and pending certain closing conditions.
Initial definitive agreement for the acquisition was signed on September 29, 2025.
👀 What to Watch
Investors should view this as a minor administrative delay in the acquisition process. Monitor for the final completion announcement by February 2026 to ensure the strategic expansion into the European market remains on track.
Lupin Signs Exclusive Deal for First-in-Class Fortnightly GLP-1 Agonist in India
Lupin has entered into an exclusive licensing agreement with Gan & Lee Pharmaceuticals to commercialize Bofanglutide, a novel GLP-1 receptor agonist, in India. The drug is a potential first-in-class fortnightly (once every two weeks) injection for Type 2 diabetes and obesity management. This partnership targets a massive addressable market in India, which includes approximately 90 million diabetics and 174 million overweight adults. By offering a 50% reduction in injection frequency compared to weekly alternatives, Lupin aims to capture significant market share in the high-growth metabolic health segment.
Key Highlights
Exclusive rights to commercialize Bofanglutide, a fortnightly GLP-1 receptor agonist, in the Indian market.
Reduces injection frequency by 50% compared to existing weekly GLP-1 injectable alternatives.
Targets a massive patient base of 90 million diabetics and 174 million overweight adults in India.
Clinical data indicates weight loss efficacy comparable to or better than current GLP-1 class drugs.
Strengthens Lupin's chronic disease portfolio and establishes a foothold in the lucrative obesity segment.
👀 What to Watch
Investors should monitor the regulatory approval timeline for Bofanglutide in India as it represents a significant growth lever for Lupin's domestic formulations business. The unique fortnightly dosing provides a strong competitive moat in the rapidly expanding GLP-1 market.
Lupin Signs Exclusive Licensing Deal for Plasil® in Philippines and Brazil
Lupin Limited has entered into an exclusive licensing agreement with Italy-based Neopharmed Gentili S.p.A for the gastroenterology brand Plasil® (metoclopramide). The agreement covers marketing and promotional rights in the Philippines and Brazil through Lupin's subsidiaries, Multicare Pharmaceuticals and MedQuimica. A key strategic component includes shifting the production for the Brazilian market to Lupin's own Medquimica manufacturing facility. This move is designed to strengthen Lupin's gastrointestinal portfolio and presence in high-growth emerging markets.
Key Highlights
Exclusive licensing for the gastroenterology brand Plasil® in the Philippines and Brazil.
Partnership with Neopharmed Gentili S.p.A to leverage local commercial capabilities.
Localization of manufacturing for the Brazilian market at Lupin's Medquimica facility.
Strategic expansion into the anti-emetic and motility disorder treatment segment in emerging markets.
👀 What to Watch
Investors should monitor the revenue contribution from these new territories as Lupin leverages its existing distribution network. The shift to in-house manufacturing in Brazil could potentially lead to better margins for this product line over time.
Lupin Receives Positive CHMP Opinion for Biosimilar Ranibizumab in Europe
Lupin has received a positive recommendation from the EMA's CHMP for its biosimilar ranibizumab, Ranluspec, for treating various retinal diseases. The recommendation is based on a successful 600-patient global phase III clinical trial demonstrating similarity to the reference product. Once the European Commission grants final approval, the product will be commercialized by Sandoz Group AG across most of the EU. This milestone marks a significant expansion of Lupin's biologics portfolio into the European market.
Key Highlights
Received positive CHMP opinion for biosimilar ranibizumab (Ranluspec) for vial and pre-filled syringe.
Clinical similarity confirmed through a 600-patient global phase III trial across US, EU, Russia, and India.
Partnership with Sandoz Group AG for commercialization in the EU (excluding Germany).
Indications include wet AMD, diabetic macular edema, and retinal vein occlusion.
👀 What to Watch
This is a significant regulatory win that paves the way for entry into the lucrative European biologics market. Investors should monitor the final EC approval and the subsequent commercial rollout by Sandoz for revenue impact.
Lupin Secures SBTi Validation; Targets 42% Scope 1 & 2 Emission Reduction by FY 2030
Lupin Limited has received official validation from the Science Based Targets initiative (SBTi) for its greenhouse gas emission reduction targets across all three scopes. The company aims to reduce absolute Scope 1 and 2 emissions by 42.0% by FY 2030, using FY 2023 as the base year. Additionally, it has committed to a 61.07% reduction in Scope 3 emissions by FY 2033 from an FY 2024 baseline. This validation aligns Lupin with the Paris Agreement's 1.5°C goal and significantly enhances its ESG profile for global institutional investors.
Key Highlights
Validated target to reduce absolute Scope 1 and 2 GHG emissions by 42.0% by FY 2030 from a FY 2023 base.
Committed to a 61.07% reduction in Scope 3 GHG emissions by FY 2033 from a FY 2024 baseline.
Targets are aligned with the 1.5°C pathway, the most ambitious goal of the Paris Agreement.
Validation covers comprehensive categories including purchased goods, fuel-related activities, and transportation.
Achieved SBTi validation within one year of setting initial climate targets.
👀 What to Watch
Investors should recognize this as a strengthening of Lupin's ESG credentials, which is increasingly critical for attracting global institutional capital. Monitor how the company balances the capital expenditure required for renewable energy and low-carbon technologies with its operational margins.
